

Reviewer#1: 1. Please mention the type of treatment in the title of manuscript. 2. Please mention the dosage and adverse events of drugs.

Reviewer 1: Please mention the type of treatment in the title.

Response to reviewer 1: We have added the type of treatment in the title and have revised the title to "Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: a case report".

Reviewer 1: page 4, line 105, Imaging examinations, it should be pathologic examinations?

Response to reviewer 1: The title was set up by the journal.

Reviewer 1: page 4, line 107, it should be lumen, not lumn.

Response to reviewer 1: We apologize for the error and we have corrected the error.

Reviewer 1: page 5, line 117, it should be pembrolizumab, not pabolizumab.

Response to reviewer 1: We apologize for the error and have corrected the error.

Reviewer 1: dosage for pembrolizumab and axitinib?

Response to reviewer 1: We have rewritten the outcome and follow-up and added the dosage. 200 mg pembrolizumab was administered to the patient through intravenous infusion once every 3 weeks combined with axitinib 5mg twice a day orally. After 8 weeks of treatment, the skin lesion was 0.6cm×0.6cm×0.4cm.

Reviewer 1: Do you have any adverse event?

Response to reviewer 1: We have added the adverse event. Upon subsequent follow-up, his lesion remained 0.6cm×0.6cm×0.4cm and there were no new lesions. Unfortunately, he died of multiple organ failure in December 2022.

Reviewer#2: The study was conducted in accordance with ethical rules. Statistical analyzes are suitable for research. Resources are related to the study. There is no salamization.

Answer: Thanks for your comments.